-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the prevention and treatment of colorectal cancer has made significant progress, in 2021 the United States is expected to die from colorectal cancer to 52,980, and the global death toll from colorectal cancer will exceed 915,880.
Colorectal cancer prevention
Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .
Recently, researchers investigated the effect of adding celecoxib to the adjuvant chemotherapy regimen of fluorouracil, calcium leucovorin and oxaliplatin (FOLFOX) on the disease-free survival rate of patients with stage III colon cancer .
This phase III clinical study was carried out in the United States and Canada.
medsci.
The 3-year disease-free survival rate of patients in the celecoxib group was 76.
Differences in disease-free survival and overall survival between groups
For patients with stage III colon cancer, adding celecoxib to the FOLFOX standard adjuvant chemotherapy regimen has no effect on the 3-year disease-free survival rate of patients .
For patients with stage III colon cancer, adding celecoxib to the FOLFOX standard adjuvant chemotherapy regimen does not improve the patient's 3-year disease-free survival rate.
Original source
Jeffrey A.
com/journals/jama/article-abstract/2778113" target="_blank" rel="noopener">Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
JAMA
Leave a message here